Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
- Conditions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2012-07-24
- Target Recruit Count
- 18
- Registration Number
- NCT00006121
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇦🇹Kaiser Franz Josef Hospital, Vienna (Wien), Austria
🇧🇪Institut Jules Bordet, Brussels (Bruxelles), Belgium
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2200
- Registration Number
- NCT00070122
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00070265
- Locations
- 🇺🇸
University of Texas, Houston, Texas, United States
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 460
- Registration Number
- NCT00070213
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧Cookridge Hospital, Leeds, England, United Kingdom
🇬🇧Clinical Trials and Research Unit of the University of Leeds, Leeds, England, United Kingdom
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00070434
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-25
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1691
- Registration Number
- NCT00003594
- Locations
- 🇺🇸
Hematology Oncology Associates of Illinois - Lake Shore Dr, Chicago, Illinois, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1886
- Registration Number
- NCT00069121
- Locations
- 🇺🇸
New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States
🇺🇸Innovative clinical research institute/American institute of research, Whittier, California, United States
🇺🇸Nh Oncology Hematology, Pa, Hooksett, New Hampshire, United States
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 627
- Registration Number
- NCT00069108
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
- Conditions
- Rectal Signet Ring Cell AdenocarcinomaStage IIA Rectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Rectal Mucinous AdenocarcinomaRecurrent Rectal CarcinomaStage IIC Rectal Cancer AJCC v7Stage IIB Rectal Cancer AJCC v7Stage IVA Rectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 225
- Registration Number
- NCT00068692
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00066625
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.